AI Article Synopsis

  • Managing chronic hepatitis B virus (HBV) infection is essential for the goal of eliminating viral hepatitis by 2030, but challenges like medication access and adherence issues persist.* -
  • A specific case study highlights a patient with both HBV and HIV who faced virological breakthrough despite receiving nucleos/tide analogue therapy due to factors like high viral load and interruptions in therapy.* -
  • The situation illustrates the need for personalized treatment plans and better support systems, especially for marginalized groups, along with comprehensive data collection to enhance patient care and retention.*

Article Abstract

Diagnosing and treating chronic hepatitis B virus (HBV) infection are key interventions to support progress towards elimination of viral hepatitis by 2030. Although nucleos/tide analogue (NA) therapy is typically highly effective, challenges remain for viral load (VL) suppression, including medication access, incomplete adherence and drug resistance. We present a case of a long-term HBV and HIV coinfected adult prescribed with sequential NA therapy regimens, with episodes of breakthrough viraemia. Multiple factors contribute to virological breakthrough, including exposure to old NA agents, initial high HBV VL, therapy interruptions, intercurrent illnesses and potential contribution from resistance mutations. The case underscores the importance of individualised treatment approaches and adherence support in achieving HBV suppression. Furthermore, it emphasises the need for improved clinical pathways addressing education, support and access to care, particularly for marginalised populations. Comprehensive data collection inclusive of under-represented individuals is crucial for maintaining retention in the care cascade and informing effective interventions.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7617237PMC
http://dx.doi.org/10.1136/sextrans-2024-056168DOI Listing

Publication Analysis

Top Keywords

nucleos/tide analogue
8
analogue therapy
8
hbv
5
multiple risk
4
risk factors
4
factors persistent
4
persistent hbv
4
hbv viraemia
4
viraemia adult
4
adult receiving
4

Similar Publications

Background: Notable advances have been made in immune checkpoint inhibitors (ICIs) for cancer treatment. However, the adverse effects of ICIs, especially hepatotoxicity, remain a challenging problem. Whether patients in hepatitis B virus (HBV)-endemic areas are prone to developing hepatic adverse events during ICI treatment warrants further exploration.

View Article and Find Full Text PDF
Article Synopsis
  • Optimizing treatment for hepatitis B is crucial for global efforts to eliminate viral hepatitis as a public health issue, as effective therapies like tenofovir and entecavir show varying success among patients.
  • Factors such as social barriers, stigma, low health awareness, and comorbidities contribute to inconsistent treatment results, especially in vulnerable populations.
  • Understanding the complexities of drug resistance and the socioeconomic challenges that affect therapy adherence is essential for improving treatment outcomes and ensuring equitable healthcare access.
View Article and Find Full Text PDF

A systematic review and meta-analysis of the risk of hepatitis B virus (HBV) resistance in people treated with entecavir or tenofovir.

J Clin Virol

October 2024

The Francis Crick Institute, 1 Midland Road, London, UK; Department of Infectious Diseases, University College London Hospitals, London, UK; Division of Infection and Immunity, University College London, Gower Street, London, UK.

Background: As nucleos/tide analogue (NA) therapy (e.g. entecavir and tenofovir) for chronic Hepatitis B virus (HBV) infection becomes more widely indicated and available, understanding drug resistance is essential.

View Article and Find Full Text PDF
Article Synopsis
  • Managing chronic hepatitis B virus (HBV) infection is essential for the goal of eliminating viral hepatitis by 2030, but challenges like medication access and adherence issues persist.* -
  • A specific case study highlights a patient with both HBV and HIV who faced virological breakthrough despite receiving nucleos/tide analogue therapy due to factors like high viral load and interruptions in therapy.* -
  • The situation illustrates the need for personalized treatment plans and better support systems, especially for marginalized groups, along with comprehensive data collection to enhance patient care and retention.*
View Article and Find Full Text PDF

Systemic cytokine and viral antigen-specific responses in hepatitis D virus RNA positive versus HDV RNA negative patients.

Front Med (Lausanne)

October 2023

Department of Microbiology, Immunology and Infectious Diseases, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada.

Background: Hepatitis B virus (HBV)/Hepatitis D Virus (HDV) co-infection increases the risk of severe liver disease compared to HBV mono-infection. Adaptive immune responses to HDV are weakly detectable, and the involvement of innate immunity in the progression of HDV-related liver fibrosis is suggested. We hypothesize that an overall innate immune activation in HBV/HDV co-infection plays a role in liver disease progression and also impacts virus specific T cell response.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!